NeuroPace (NPCE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Voting matters and shareholder proposals
Election of two Class II director nominees, Lisa Andrade and Scott Huennekens, to serve until the 2029 Annual Meeting and until successors are elected and qualified.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Two director nominees are up for election to the board, each for a term expiring at the 2029 Annual Meeting.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NeuroPace
- Proxy covers director elections, auditor ratification, and robust governance and compensation policies.NPCE
Proxy filing21 Apr 2026 - 2026 is set to be a pivotal year, driven by new indications, AI tools, and expanding market reach.NPCE
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Strong 2025 results and 2026 outlook driven by RNS growth, margin gains, and innovation pipeline.NPCE
Q4 20254 Mar 2026 - $100M 2025 revenue, 25% growth, and AI-driven RNS therapy fuel strong expansion.NPCE
Investor presentation3 Mar 2026 - Q2 2024 revenue up 17% to $19.3M, margin 73.4%, net loss narrowed, and guidance raised.NPCE
Q2 20241 Feb 2026 - Three-part strategy and clinical expansion drive growth and position for leadership in epilepsy care.NPCE
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - RNS delivers tailored, data-driven epilepsy therapy with strong growth and expansion plans.NPCE
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - 2025 revenue hit $100M with 25% growth, advancing AI-driven therapy and market expansion.NPCE
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Q3 revenue up 28% year-over-year, guidance raised on strong RNS System and DIXI sales.NPCE
Q3 202414 Jan 2026